US FDA panel rejects Acura/King's abuse-deterrent analgesic
This article was originally published in Scrip
Executive Summary
A US FDA advisory panel overwhelmingly recommended against approval of Acura Pharmaceuticals/King Pharmaceuticals' Acurox (oxycodone plus niacin) for the treatment of moderate to severe pain, citing inadequate evidence that inclusion of niacin in the combination product would deter misuse or abuse of the opioid oxycodone.